Close

New Report Demonstrates High Costs and Low Benefits of Sarbanes-Oxley 404(b) Compliance for Emerging Biotechs

Feb 11 2019
To recognize National Inventors’ Day, the Biotechnology Innovation Organization (BIO) released a new report, “Science or Compliance: Will Section 404(b) Compliance Impede Innovation by Emerging Growth Companies in the Biotech Industry?” The report shows the detrimental impact of Sarbanes-Oxley 404(b) on biopharmaceutical emerging growth companies (Bio-EGCs) and demonstrates how this regulatory requirement harms innovation and capital formation without any corresponding investor benefit. 

BIO Encouraged by Improved U.S. Ranking in Global Index of Patent System Strength

Feb 7 2019
But New Legislative Proposals Endanger Progress

BIO Statement on Hatch-Waxman Integrity Act of 2019

Feb 7 2019
BIO applauds the leadership of Senator Thom Tillis (R- NC) and Congressman Bill Flores (R-17 TX) for introducing the “Hatch-Waxman Integrity Act of 2019” to preserve the time-tested approach of the HWA while strengthening the ability of patent owners to fairly defend against abusive efforts to invalidate patents for innovative life-saving medical therapies.

BIO Statement on State of the Union Address

Feb 5 2019
BIO’s President and CEO Jim Greenwood issues statement on President Trump’s State of the Union Address.

BIO Statement on New Proposal for Lowering Out-of-Pocket Costs for Medicines

Jan 31 2019
BIO’s President and CEO Jim Greenwood issued a statement after the Trump administration released a proposed rule that would alter safe harbor policies under the federal anti-kickback statute.

BIO Statement Ahead of Chinese Vice Premier Visit to Washington

Jan 29 2019
Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement ahead of Chinese Vice Premier Liu He's visit to Washington to participate in trade negotiations on Wednesday and Thursday. 

BIO Statement on China Approvals of Agricultural Biotechnology Products

Jan 17 2019
Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement on the announcement that the People’s Republic of China’s National Biosafety Committee approved the final safety certificate for five agricultural biotechnology products.

New Platform for Innovation in Food and Agriculture Launches, Invites Broad Conversation

Jan 16 2019
WASHINGTON, DC – Jan. 16, 2019 – Today, the Biotechnology Innovation Organization (BIO) and the American Seed Trade Association (ASTA) jointly announce the launch of Innovature, a new platform to spark a thoughtful dialogue around innovation in food and agriculture, with an initial focus on gene editing. Growing understanding of gene editing is spurring new developments in food and agriculture to address some of our most pressing societal challenges.

BIO Applauds House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act

Jan 11 2019
“Members of the House have sent a strong signal to the American people about their commitment to prioritizing health security by providing the resources needed to fully prepare for and defend against biological threats. Strengthening the pipeline of medical products, drugs and devices that will safeguard the nation during an emergency or pandemic is vital to our national security."

BIO Applauds House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act

Dec 20 2018
Washington, DC (December 20, 2018) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement applauding passage today by the House of Representatives of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (H.R. 7328). The legislation would re-authorize critical federal biodefense programs and agencies, including the BioShield Special Reserve Fund (SRF), the Biomedical Advanced Research and Development Authority (BARDA), and the Strategic National Stockpile (SNS).